Advertisement

Current Allergy and Asthma Reports

, Volume 7, Issue 1, pp 35–40 | Cite as

Allergic reactions to nonsteroidal anti-inflammatory drugs: Is newer better?

  • M. Pilar Berges-Gimeno
  • Joaquín Martín-Lázaro
Article

Abstract

In clinical practice, physicians may find it difficult to recognize the differences between allergic and pseudoallergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) and to manage each type of reaction. This paper reviews all the information presently available in order to clarify main problems related to NSAID reactions and to highlight key strategies to handle these reactions.

Keywords

Celecoxib Rofecoxib Allergy Clin Immunol Chronic Urticaria Etoricoxib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Stevenson D, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001, 87:177–180.PubMedGoogle Scholar
  2. 2.
    McDonald JR, Mathison DA, Stevenson DD: Aspirin intolerance in asthma, detection by oral challenge. J Allergy Clin Immunol 1972, 50:198–207.PubMedCrossRefGoogle Scholar
  3. 3.
    Christie PE, Tagari P, Ford-Hutchinson AW, et al.: Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991, 143:1025–1029.PubMedGoogle Scholar
  4. 4.
    Berges-Gimeno MP, Simon RA, Stevenson DD: The natural history and clinical characteristics-of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunology 2002, 89:474–478.Google Scholar
  5. 5.
    Szczeklik A, Nizankowska M, Duplaga M, et al.: Natural history of aspirin-induced asthma. Eur Respir J 2000, 16:432–436.PubMedCrossRefGoogle Scholar
  6. 6.
    Mastarlerz L, Setkowicz M, Sanak M, Szczeklik A: Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004, 113:771–775.CrossRefGoogle Scholar
  7. 7.
    Mathison DA, Lumry WR, Stevenson DD, et al.: Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitization. J Allergy Clin Immunol 1982, 69:135.CrossRefGoogle Scholar
  8. 8.
    Szczeklik A: Analgesics, allergy and asthma. Drugs 1986, 4:148–163.Google Scholar
  9. 9.
    Daxum Z, Becker WM, Schulz KH, Schlaak M: Sensitivity to aspirin: a new serologic diagnostic method. J Investigational Allergol Clin Immunol 1993, 3:72–78.Google Scholar
  10. 10.
    Kowalski ML, Bienkiewicz B, Woeszcek G: Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc 1999, 20:347–352.PubMedCrossRefGoogle Scholar
  11. 11.
    Asero R: Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003, 111:1095–1098.PubMedCrossRefGoogle Scholar
  12. 12.
    Levy M, Fink J: Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001, 87:72–73.PubMedGoogle Scholar
  13. 13.
    Grob M, Pichler WJ, Wuthrich B: Anaphylaxis to celecoxib. Allergy 2002, 57:264–265.PubMedCrossRefGoogle Scholar
  14. 14.
    Fontaine C, Bousquet PJ, Demoly P: Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol 2005, 115:633–634.PubMedCrossRefGoogle Scholar
  15. 15.
    Szczeklik A, Stevenson DD: Aspirin induced asthma: advances and pathogenesis and management. J Allergy Clin Immunol 1999, 104:5–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshida S, Ishizaki Y, Omuma K: Selective cyclo.oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000, 106:1201–1202.PubMedCrossRefGoogle Scholar
  17. 17.
    Dahlen B, Szczeklik A, Murray JJ: Celecoxib in patients with asthma and aspirin intolerance. New Engl J Med 2001, 344:142.PubMedCrossRefGoogle Scholar
  18. 18.
    Szczeklik A, Nizankowska E, Bochenek G, et al.: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001, 31:219–225.PubMedCrossRefGoogle Scholar
  19. 19.
    Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001, 108:47–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002, 46:2201–2206.PubMedCrossRefGoogle Scholar
  21. 21.
    Martín-García C, Hinojosa M, Berges P, et al.: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002, 121:1812–1817.PubMedCrossRefGoogle Scholar
  22. 22.
    Martín-García C, Hinojosa M, Berges P, et al.: Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003, 13:20–25.PubMedGoogle Scholar
  23. 23.
    Gyllfors P, Bochenek G, Overholt J, et al.: Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003, 111:1116–1121.PubMedCrossRefGoogle Scholar
  24. 24.
    Valero A, Enrique E, Baltasar M, et al.: Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions. Med Clin (Barc) 2003, 121:695–696.CrossRefGoogle Scholar
  25. 25.
    Woessner KM, Simon RA, Stevenson DD: Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004, 93:339–344.PubMedGoogle Scholar
  26. 26.
    Micheletto C, Tognella S, Guerriero M, Dal Negro R: Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. Allerg Immunol (Paris) 2006, 38:10–14.Google Scholar
  27. 27.
    Asero R: Tolerability of rofecoxib. Allergy 2001, 56:916–917.PubMedCrossRefGoogle Scholar
  28. 28.
    Berges-Gimeno MP, Camacho-Garrido E, García-Rodríguez RM, et al.: Rofecoxib safe in NSAID hypersensitivity. Allergy 2001, 56:1017–1018.PubMedCrossRefGoogle Scholar
  29. 29.
    Nettis E, Di PR, Ferrannini A, Tursi A: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002, 88:331–334.PubMedGoogle Scholar
  30. 30.
    Pacor ML, Di Lorenzo G, Biasi D, et al.: Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002, 32:397–400.PubMedCrossRefGoogle Scholar
  31. 31.
    Quiralte J, Saenz de San Pedro B, Florido JJ: Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002, 89:63–66.PubMedGoogle Scholar
  32. 32.
    García-Rodríguez RM, Hinojosa M, Camacho-Garrido E, Berges Gimeno P, Martín García C. Celecoxib, safe in NSAID intolerance. Allergy 2002; 57:1085–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Nettis E, Colanardi MC, Ferrannini A, Tursi A: Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005, 94:29–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005, 95:154–158.PubMedGoogle Scholar
  35. 35.
    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005, 94:34–38.PubMedGoogle Scholar
  36. 36.
    Quiralte J, Delgado J, Saenz de San Pedro B, et al.: Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004, 93:360–364.PubMedGoogle Scholar
  37. 37.
    Simon RA: Adverse respiratory reactions to Aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004, 4:17–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Berges-Gimeno MP, Simon RA, Stevenson DD: Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003, 90:338–341.PubMedGoogle Scholar
  39. 39.
    Berges-Gimeno MP, Simon RA, Stevenson DD: Long term treatment with aspirin desensitization in asthmatics with aspirin exacerbated respiratory disease. J Allergy Clin Immunol 2003, 111:180–186.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • M. Pilar Berges-Gimeno
    • 1
  • Joaquín Martín-Lázaro
  1. 1.Hospital Ramón y CajalMadridSpain

Personalised recommendations